PMID- 32486367
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 9
IP  - 6
DP  - 2020 May 31
TI  - Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations are 
      Elevated in Patients with Neuroendocrine Malignancies.
LID - 10.3390/jcm9061647 [doi]
LID - 1647
AB  - Neuroendocrine neoplasia (NEN) comprises heterogeneous tumors that are 
      challenging to diagnose and, especially in cases of poorly differentiated (G3) 
      NEN, are associated with very limited survival. Novel biomarkers allowing an 
      early diagnosis as well as an optimal selection of suitable treatment options are 
      urgently needed to improve the outcome of these patients. Recently, alterations 
      of soluble urokinase-type plasminogen activator receptor (suPAR) serum levels 
      were described in various types of cancers. However, the role of circulating 
      suPAR as a biomarker in patients with NEN is unknown. In this study, we measured 
      suPAR serum levels in a large and well-characterized cohort of 187 patients with 
      NEN (neuroendocrine carcinomas (NEC) n = 30; neuroendocrine tumors (NET), n = 
      157) as well as 44 healthy controls. suPAR concentrations were significantly 
      elevated in patients compared to controls. However, suPAR concentrations were 
      independent of tumor-related factors such as the proliferation activity according 
      to Ki-67, tumor grading, TNM (TNM classification of malignant tumors) stage, 
      somatostatin receptor expression or clinical features such as functional or 
      nonfunctional disease and the presence of tumor relapse. Interestingly, suPAR 
      concentrations in NET patients were similar when compared to those measured in 
      NEC patients. In contrast to previous results from other malignancies, in our 
      analysis suPAR levels were not a significant predictor of overall survival. In 
      conclusion, our data suggests that suPAR serum concentrations are elevated in NEN 
      patients but do not allow prediction of outcome.
FAU - Ozdirik, Burcin
AU  - Ozdirik B
AUID- ORCID: 0000-0002-8885-737X
AD  - Department of Hepatology and Gastroenterology, Campus Virchow Klinikum and Campus 
      Charite Mitte, Charite University Medicine Berlin, 13353 Berlin, Germany.
FAU - Stueven, Anna
AU  - Stueven A
AD  - Department of Hepatology and Gastroenterology, Campus Virchow Klinikum and Campus 
      Charite Mitte, Charite University Medicine Berlin, 13353 Berlin, Germany.
FAU - Knorr, Jana
AU  - Knorr J
AD  - Department of Hepatology and Gastroenterology, Campus Virchow Klinikum and Campus 
      Charite Mitte, Charite University Medicine Berlin, 13353 Berlin, Germany.
FAU - Geisler, Lukas
AU  - Geisler L
AD  - Department of Hepatology and Gastroenterology, Campus Virchow Klinikum and Campus 
      Charite Mitte, Charite University Medicine Berlin, 13353 Berlin, Germany.
FAU - Mohr, Raphael
AU  - Mohr R
AD  - Department of Hepatology and Gastroenterology, Campus Virchow Klinikum and Campus 
      Charite Mitte, Charite University Medicine Berlin, 13353 Berlin, Germany.
FAU - Demir, Munevver
AU  - Demir M
AD  - Department of Hepatology and Gastroenterology, Campus Virchow Klinikum and Campus 
      Charite Mitte, Charite University Medicine Berlin, 13353 Berlin, Germany.
FAU - Hellberg, Teresa
AU  - Hellberg T
AD  - Department of Hepatology and Gastroenterology, Campus Virchow Klinikum and Campus 
      Charite Mitte, Charite University Medicine Berlin, 13353 Berlin, Germany.
FAU - Loosen, Sven H
AU  - Loosen SH
AUID- ORCID: 0000-0003-3447-1161
AD  - Department of Medicine III, University Hospital RWTH Aachen, Pauwelsstrasse 30, 
      52074 Aachen, Germany.
FAU - Benz, Fabian
AU  - Benz F
AD  - Department of Hepatology and Gastroenterology, Campus Virchow Klinikum and Campus 
      Charite Mitte, Charite University Medicine Berlin, 13353 Berlin, Germany.
FAU - Wiedenmann, Bertram
AU  - Wiedenmann B
AD  - Department of Hepatology and Gastroenterology, Campus Virchow Klinikum and Campus 
      Charite Mitte, Charite University Medicine Berlin, 13353 Berlin, Germany.
FAU - Tacke, Frank
AU  - Tacke F
AUID- ORCID: 0000-0001-6206-0226
AD  - Department of Hepatology and Gastroenterology, Campus Virchow Klinikum and Campus 
      Charite Mitte, Charite University Medicine Berlin, 13353 Berlin, Germany.
FAU - Wree, Alexander
AU  - Wree A
AD  - Department of Hepatology and Gastroenterology, Campus Virchow Klinikum and Campus 
      Charite Mitte, Charite University Medicine Berlin, 13353 Berlin, Germany.
FAU - Jann, Henning
AU  - Jann H
AD  - Department of Hepatology and Gastroenterology, Campus Virchow Klinikum and Campus 
      Charite Mitte, Charite University Medicine Berlin, 13353 Berlin, Germany.
FAU - Roderburg, Christoph
AU  - Roderburg C
AD  - Department of Hepatology and Gastroenterology, Campus Virchow Klinikum and Campus 
      Charite Mitte, Charite University Medicine Berlin, 13353 Berlin, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200531
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC7355627
OTO - NOTNLM
OT  - biomarker
OT  - neuroendocrine carcinoma
OT  - neuroendocrine tumor
OT  - soluble urokinase-type plasminogen activator receptor
OT  - survival
COIS- The authors declare no conflict of interest.
EDAT- 2020/06/04 06:00
MHDA- 2020/06/04 06:01
PMCR- 2020/05/31
CRDT- 2020/06/04 06:00
PHST- 2020/05/05 00:00 [received]
PHST- 2020/05/18 00:00 [revised]
PHST- 2020/05/25 00:00 [accepted]
PHST- 2020/06/04 06:00 [entrez]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2020/06/04 06:01 [medline]
PHST- 2020/05/31 00:00 [pmc-release]
AID - jcm9061647 [pii]
AID - jcm-09-01647 [pii]
AID - 10.3390/jcm9061647 [doi]
PST - epublish
SO  - J Clin Med. 2020 May 31;9(6):1647. doi: 10.3390/jcm9061647.